Form 4 for GNLX GENELUX Corp
Accepted 2025-05-13 00:00:00 ET · period of report 2025-05-12 · accession 0001415889-25-012807 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-13 | 2025-05-12 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $2.92 | -5,579 | 47.6K | -10% | -$16.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-12 | S | D | 5,579 | $2.92 | 47,640 | D | — | — |